Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.

Between August 1989 and November 2003, 33 patients at our center with acquired aplastic anemia underwent bone marrow transplantation (BMT) from HLA-identical sibling donors with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies (MoAb) for conditioning. The median age at BMT was 17 years (...

Full description

Bibliographic Details
Main Authors: Gupta, V, Ball, SE, Yi, Q, Sage, D, McCann, SR, Lawler, M, Ortin, M, Freires, M, Hale, G, Waldmann, H, Gordon-Smith, E, Marsh, J
Format: Journal article
Language:English
Published: 2004
_version_ 1797094460140552192
author Gupta, V
Ball, SE
Yi, Q
Sage, D
McCann, SR
Lawler, M
Ortin, M
Freires, M
Hale, G
Waldmann, H
Gordon-Smith, E
Marsh, J
author_facet Gupta, V
Ball, SE
Yi, Q
Sage, D
McCann, SR
Lawler, M
Ortin, M
Freires, M
Hale, G
Waldmann, H
Gordon-Smith, E
Marsh, J
author_sort Gupta, V
collection OXFORD
description Between August 1989 and November 2003, 33 patients at our center with acquired aplastic anemia underwent bone marrow transplantation (BMT) from HLA-identical sibling donors with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies (MoAb) for conditioning. The median age at BMT was 17 years (range, 4-46 years). Before BMT, 58% were heavily transfused (>50 transfusions), and 42% had previously experienced treatment failure with antithymocyte globulin-based immunosuppressive therapy. Unmanipulated bone marrow was used as the source of stem cells in all patients except 1. Graft-versus-host disease (GVHD) prophylaxis was with cyclosporine alone in 19 (58%) patients; 14 received anti-CD52 MoAb in addition to cyclosporine. The conditioning regimen was well tolerated without significant acute toxicity. Graft failure was seen in 8 patients (primary, n = 4; secondary, n = 4). Of those whose grafts failed, 4 survived long-term (complete autologous recovery, n = 2; rescue with previously stored marrow, n = 1; second allograft, n = 1). The cumulative incidence of graft failure and grade II to IV acute and chronic GVHD was 24%, 14%, and 4%, respectively. None developed extensive chronic GVHD. With a median follow-up of 59 months, the 5-year survival was 81% (95% confidence interval, 68%-96%). No unexpected early or late infectious or noninfectious complications were observed. We conclude that the conditioning regimen containing cyclophosphamide and anti-CD52 MoAb is well tolerated and effective for acquired aplastic anemia with HLA-matched sibling donors. The favorable effect on the incidence and severity of GVHD is noteworthy in this study and warrants further investigation.
first_indexed 2024-03-07T04:14:22Z
format Journal article
id oxford-uuid:c8ea4562-7663-41ba-9ad6-d2d4dc24ae04
institution University of Oxford
language English
last_indexed 2024-03-07T04:14:22Z
publishDate 2004
record_format dspace
spelling oxford-uuid:c8ea4562-7663-41ba-9ad6-d2d4dc24ae042022-03-27T06:55:24ZFavorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c8ea4562-7663-41ba-9ad6-d2d4dc24ae04EnglishSymplectic Elements at Oxford2004Gupta, VBall, SEYi, QSage, DMcCann, SRLawler, MOrtin, MFreires, MHale, GWaldmann, HGordon-Smith, EMarsh, JBetween August 1989 and November 2003, 33 patients at our center with acquired aplastic anemia underwent bone marrow transplantation (BMT) from HLA-identical sibling donors with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies (MoAb) for conditioning. The median age at BMT was 17 years (range, 4-46 years). Before BMT, 58% were heavily transfused (>50 transfusions), and 42% had previously experienced treatment failure with antithymocyte globulin-based immunosuppressive therapy. Unmanipulated bone marrow was used as the source of stem cells in all patients except 1. Graft-versus-host disease (GVHD) prophylaxis was with cyclosporine alone in 19 (58%) patients; 14 received anti-CD52 MoAb in addition to cyclosporine. The conditioning regimen was well tolerated without significant acute toxicity. Graft failure was seen in 8 patients (primary, n = 4; secondary, n = 4). Of those whose grafts failed, 4 survived long-term (complete autologous recovery, n = 2; rescue with previously stored marrow, n = 1; second allograft, n = 1). The cumulative incidence of graft failure and grade II to IV acute and chronic GVHD was 24%, 14%, and 4%, respectively. None developed extensive chronic GVHD. With a median follow-up of 59 months, the 5-year survival was 81% (95% confidence interval, 68%-96%). No unexpected early or late infectious or noninfectious complications were observed. We conclude that the conditioning regimen containing cyclophosphamide and anti-CD52 MoAb is well tolerated and effective for acquired aplastic anemia with HLA-matched sibling donors. The favorable effect on the incidence and severity of GVHD is noteworthy in this study and warrants further investigation.
spellingShingle Gupta, V
Ball, SE
Yi, Q
Sage, D
McCann, SR
Lawler, M
Ortin, M
Freires, M
Hale, G
Waldmann, H
Gordon-Smith, E
Marsh, J
Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.
title Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.
title_full Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.
title_fullStr Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.
title_full_unstemmed Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.
title_short Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.
title_sort favorable effect on acute and chronic graft versus host disease with cyclophosphamide and in vivo anti cd52 monoclonal antibodies for marrow transplantation from hla identical sibling donors for acquired aplastic anemia
work_keys_str_mv AT guptav favorableeffectonacuteandchronicgraftversushostdiseasewithcyclophosphamideandinvivoanticd52monoclonalantibodiesformarrowtransplantationfromhlaidenticalsiblingdonorsforacquiredaplasticanemia
AT ballse favorableeffectonacuteandchronicgraftversushostdiseasewithcyclophosphamideandinvivoanticd52monoclonalantibodiesformarrowtransplantationfromhlaidenticalsiblingdonorsforacquiredaplasticanemia
AT yiq favorableeffectonacuteandchronicgraftversushostdiseasewithcyclophosphamideandinvivoanticd52monoclonalantibodiesformarrowtransplantationfromhlaidenticalsiblingdonorsforacquiredaplasticanemia
AT saged favorableeffectonacuteandchronicgraftversushostdiseasewithcyclophosphamideandinvivoanticd52monoclonalantibodiesformarrowtransplantationfromhlaidenticalsiblingdonorsforacquiredaplasticanemia
AT mccannsr favorableeffectonacuteandchronicgraftversushostdiseasewithcyclophosphamideandinvivoanticd52monoclonalantibodiesformarrowtransplantationfromhlaidenticalsiblingdonorsforacquiredaplasticanemia
AT lawlerm favorableeffectonacuteandchronicgraftversushostdiseasewithcyclophosphamideandinvivoanticd52monoclonalantibodiesformarrowtransplantationfromhlaidenticalsiblingdonorsforacquiredaplasticanemia
AT ortinm favorableeffectonacuteandchronicgraftversushostdiseasewithcyclophosphamideandinvivoanticd52monoclonalantibodiesformarrowtransplantationfromhlaidenticalsiblingdonorsforacquiredaplasticanemia
AT freiresm favorableeffectonacuteandchronicgraftversushostdiseasewithcyclophosphamideandinvivoanticd52monoclonalantibodiesformarrowtransplantationfromhlaidenticalsiblingdonorsforacquiredaplasticanemia
AT haleg favorableeffectonacuteandchronicgraftversushostdiseasewithcyclophosphamideandinvivoanticd52monoclonalantibodiesformarrowtransplantationfromhlaidenticalsiblingdonorsforacquiredaplasticanemia
AT waldmannh favorableeffectonacuteandchronicgraftversushostdiseasewithcyclophosphamideandinvivoanticd52monoclonalantibodiesformarrowtransplantationfromhlaidenticalsiblingdonorsforacquiredaplasticanemia
AT gordonsmithe favorableeffectonacuteandchronicgraftversushostdiseasewithcyclophosphamideandinvivoanticd52monoclonalantibodiesformarrowtransplantationfromhlaidenticalsiblingdonorsforacquiredaplasticanemia
AT marshj favorableeffectonacuteandchronicgraftversushostdiseasewithcyclophosphamideandinvivoanticd52monoclonalantibodiesformarrowtransplantationfromhlaidenticalsiblingdonorsforacquiredaplasticanemia